Aclaris Therapeutics (ACRS) Profit After Tax (2014 - 2026)

Aclaris Therapeutics' Profit After Tax history runs 13 years deep, the most recent figure standing at -$19.8 million for Q1 2026.

• In Q1 2026, Profit After Tax fell 31.42% year-over-year to -$19.8 million; the TTM figure through Mar 2026 stood at -$69.7 million (up 46.5% YoY), while the FY2025 annual figure was -$64.9 million, up 50.84% from the prior year.
• Profit After Tax was -$19.8 million for Q1 2026 at Aclaris Therapeutics, roughly flat from -$19.8 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$1.5 million in Q4 2023 to a low of -$96.6 million in Q4 2024.
• Historically, Profit After Tax has averaged -$23.1 million across 5 years, with a median of -$19.8 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Profit After Tax surged 94.6% in 2023, then sank 6375.65% in 2024.
• A 5-year view of Profit After Tax shows it stood at -$27.6 million in 2022, then soared by 94.6% to -$1.5 million in 2023, then tumbled by 6375.65% to -$96.6 million in 2024, then surged by 79.5% to -$19.8 million in 2025, then decreased by 0.15% to -$19.8 million in 2026.
• The last three Profit After Tax figures came in at -$19.8 million (Q1 2026), -$19.8 million (Q4 2025), and -$14.6 million (Q3 2025), per Business Quant data.